147 related articles for article (PubMed ID: 38377818)
1. Identification of new 5-(2,6-dichlorophenyl)-3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine-7-carboxylic acids as p38α MAPK inhibitors: Design, synthesis, antitumor evaluation, molecular docking and in silico studies.
El-Wakil MH; El-Dershaby HA; Ghazallah RA; El-Yazbi AF; Abd El-Razik HA; Soliman FSG
Bioorg Chem; 2024 Apr; 145():107226. PubMed ID: 38377818
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers.
Sherbiny FF; Bayoumi AH; El-Morsy AM; Sobhy M; Hagras M
Bioorg Chem; 2021 Nov; 116():105325. PubMed ID: 34507234
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and molecular docking studies of new furochromone derivatives as p38α MAPK inhibitors targeting human breast cancer MCF-7 cells.
Amin KM; Syam YM; Anwar MM; Ali HI; Abdel-Ghani TM; Serry AM
Bioorg Med Chem; 2017 Apr; 25(8):2423-2436. PubMed ID: 28291685
[TBL] [Abstract][Full Text] [Related]
4. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
5. Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds.
Abdelhafez OM; Ahmed EY; Abdel Latif NA; Arafa RK; Abd Elmageed ZY; Ali HI
Bioorg Med Chem; 2019 Apr; 27(7):1308-1319. PubMed ID: 30792101
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis,
Matada GSP; Abbas N; Dhiwar PS; Basu R; Devasahayam G
Anticancer Agents Med Chem; 2021; 21(4):451-461. PubMed ID: 32698735
[TBL] [Abstract][Full Text] [Related]
7. One-pot synthesis of thiazolo[3,2-a]pyrimidine derivatives, their cytotoxic evaluation and molecular docking studies.
Sekhar T; Thriveni P; Venkateswarlu A; Daveedu T; Peddanna K; Sainath SB
Spectrochim Acta A Mol Biomol Spectrosc; 2020 Apr; 231():118056. PubMed ID: 32006911
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers.
Metwally NH; Mohamed MS; Ragb EA
Bioorg Chem; 2019 Jul; 88():102929. PubMed ID: 31015179
[TBL] [Abstract][Full Text] [Related]
9.
Keshari AK; Singh AK; Raj V; Rai A; Trivedi P; Ghosh B; Kumar U; Rawat A; Kumar D; Saha S
Drug Des Devel Ther; 2017; 11():1623-1642. PubMed ID: 28615927
[TBL] [Abstract][Full Text] [Related]
10. 2-Anilinopyrimidine derivatives: Design, synthesis, in vitro anti-proliferative activity, EGFR and ARO inhibitory activity, cell cycle analysis and molecular docking study.
AboulWafa OM; Daabees HMG; Badawi WA
Bioorg Chem; 2020 Jun; 99():103798. PubMed ID: 32247112
[TBL] [Abstract][Full Text] [Related]
11. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and molecular docking study of new pyrimidine-based hydrazones with selective anti-proliferative activity against MCF-7 and MDA-MB-231 human breast cancer cell lines.
Badawi WA; Samir M; Fathy HM; Okda TM; Noureldin MH; Atwa GMK; AboulWafa OM
Bioorg Chem; 2023 Sep; 138():106610. PubMed ID: 37210828
[TBL] [Abstract][Full Text] [Related]
14. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and antitumor screening of new thiazole, thiazolopyrimidine, and thiazolotriazine derivatives as potent inhibitors of VEGFR-2.
Abd Elhameed AA; Ali AR; Ghabbour HA; Bayomi SM; El-Gohary NS
Drug Dev Res; 2023 Dec; 84(8):1664-1698. PubMed ID: 37661648
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
[TBL] [Abstract][Full Text] [Related]
17. New Indazol-Pyrimidine-Based Derivatives as Selective Anticancer Agents: Design, Synthesis, and In Silico Studies.
Al-Tuwaijri HM; Al-Abdullah ES; El-Rashedy AA; Ansari SA; Almomen A; Alshibl HM; Haiba ME; Alkahtani HM
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175074
[TBL] [Abstract][Full Text] [Related]
18. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis,
Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH
Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605
[TBL] [Abstract][Full Text] [Related]
19. Pyrazolo[3,4-d]pyrimidine-based dual EGFR T790M/HER2 inhibitors: Design, synthesis, structure-activity relationship and biological activity as potential antitumor and anticonvulsant agents.
Lamie PF; El-Kalaawy AM; Abdel Latif NS; Rashed LA; Philoppes JN
Eur J Med Chem; 2021 Mar; 214():113222. PubMed ID: 33545637
[TBL] [Abstract][Full Text] [Related]
20. Synthesis, biological evaluation, and
Mandour AA; Nassar IF; Abdel Aal MT; Shahin MAE; El-Sayed WA; Hegazy M; Yehia AM; Ismail A; Hagras M; Elkaeed EB; Refaat HM; Ismail NSM
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1957-1973. PubMed ID: 35815597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
